Balloon atrial septostomy as initial therapy in pediatric pulmonary hypertension

Paul J. Critser, Patrick D. Evers, Eimear McGovern, Michelle Cash, Russel Hirsch

Research output: Contribution to journalArticlepeer-review

Abstract

Balloon atrial septostomy is a palliative procedure currently used to bridge medically refractory pulmonary hypertension patients to lung transplantation. In the current report, we present balloon atrial septostomy as an initial therapy for high-risk pediatric pulmonary hypertension patients at our institution. Nineteen patients with median age of 4.3 years (range 0.1–14.3 years) underwent balloon atrial septostomy during initial admission for pulmonary hypertension. There were no procedural complications or deaths within 24 h of balloon atrial septostomy. Patients were followed for a median of 2.6 years (interquartile range 1.0–4.8 years). Three (16%) patients died, 3 (16%) underwent lung transplantation, and 1 (5%) underwent reverse Potts shunt. Transplant-free survival at 30 days, 1 year, and 3 years was 84%, 76%, and 67% respectively. This single-center experience suggests early-BAS in addition to pharmacotherapy is safe and warrants consideration in high-risk pediatric pulmonary hypertension patients.

Original languageEnglish (US)
JournalPulmonary Circulation
Volume10
Issue number4
DOIs
StatePublished - 2020

Keywords

  • Pulmonary hypertension
  • balloon atrial septostomy
  • pediatrics

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Fingerprint

Dive into the research topics of 'Balloon atrial septostomy as initial therapy in pediatric pulmonary hypertension'. Together they form a unique fingerprint.

Cite this